BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22681918)

  • 1. [Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].
    Gao Z; Zhuang L; Chen Y
    Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):324-31. PubMed ID: 22681918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment].
    Deng J; Zhuang L; Chen Y
    Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):841-7. PubMed ID: 22104217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.
    Tanaka T; Munshi A; Brooks C; Liu J; Hobbs ML; Meyn RE
    Clin Cancer Res; 2008 Feb; 14(4):1266-73. PubMed ID: 18281562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
    Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
    Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.
    Bokobza SM; Jiang Y; Weber AM; Devery AM; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):947-54. PubMed ID: 24606853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
    Okamoto W; Okamoto I; Tanaka K; Hatashita E; Yamada Y; Kuwata K; Yamaguchi H; Arao T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Mol Cancer Ther; 2010 Oct; 9(10):2785-92. PubMed ID: 20716641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
    Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL
    J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
    Kang KB; Zhu C; Wong YL; Gao Q; Ty A; Wong MC
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e43-52. PubMed ID: 22516386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
    Kim EJ; Jeong JH; Bae S; Kang S; Kim CH; Lim YB
    J Cell Biochem; 2013 Jun; 114(6):1248-56. PubMed ID: 23592446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
    Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
    PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
    Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA
    J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
    Ahn SH; Jeong EH; Lee TG; Kim SY; Kim HR; Kim CH
    Cell Oncol (Dordr); 2014 Oct; 37(5):377-86. PubMed ID: 25228008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
    Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
    J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
    Geng L; Cuneo KC; Fu A; Tu T; Atadja PW; Hallahan DE
    Cancer Res; 2006 Dec; 66(23):11298-304. PubMed ID: 17145876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
    Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.